Table of Content

1. Introduction to PRMT5 Targeted Therapy
1.1 Overview
1.2 History & Evolution of PRMT5 Targeted Therapy


2. PRMT5 Targeted Therapy Approaches
2.1 Small Molecule Inhibitors
2.2 Protein Degraders
2.3 Small Molecule Activators


3. Role of PRMT5 Targeted Therapies by Indication
3.1 Cancers
3.1.1 Solid Cancers
3.1.2 Hematological Cancers
3.2 Autoimmune & Inflammatory Diseases
3.3 Cardiovascular Diseases
3.4 Microbial Infections


4. Global PRMT5 Targeted Therapies Clinical Trials Overview
4.1 By Company
4.2 By Indication
4.3 By Location
4.4 By Patient Segment
4.5 By Phase


5. Global PRMT5 Targeted Therapies Clinical Trials By Company, Indication & Phase
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II


6. PRMT5 Targeted Therapies Research & Market Trends by Region
6.1 US
6.2 UK
6.3 EU
6.4 China
6.5 Canada


7. PRMT5 Targeted Therapies Market Trends & Clinical Trials Outlook
7.1 Current Market Trends, Developments & Clinical Trials Assessment
7.2 Future Commercialization Opportunity


8. PRMT5 Targeted Therapies Market Dynamics
8.1 Drivers & Opportunities
8.2 Challenges & Restraints


9. Competitive Landscape
9.1 Abbisko Therapeutics
9.2 Agios Pharmaceuticals
9.3 Amgen
9.4 AstraZeneca
9.5 Aurigene Oncology
9.6 CytosinLab Therapeutics
9.7 Epizyme (Ipsen)
9.8 IngenOx Therapeutics
9.9 Johnson & Johnson
9.10 Jubilant Therapeutics
9.11 Mirati Therapeutics
9.12 Ryvu Therapeutics
9.13 Schrodinger
9.14 Simcere Pharmaceutical Group
9.15 SK Life Science
9.16 Tango Therapeutics



List of Figures

Figure 1-1: PRMT5 - Normal Functions
Figure 1-2: PRMT5 - Oncogenic Functions
Figure 1-3: PRMT5 - Important Milestones in Development

Figure 2-1: PRMT5 - Binding Sites for Small Molecule Inhibitors
Figure 2-2: PROTACs - Mechanism of Action
Figure 2-3: PROTACs - Advantages

Figure 3-1: PRMT5 – Roles in Solid Cancers
Figure 3-2: PRMT5 – Roles in Hematological Cancers
Figure 3-3: PRMT5 – Roles in Diabetes
Figure 3-4: PRMT5 – Roles in Microbial Infections

Figure 4-1: Global - PRMT5 Targeted Therapies Clinical Trials By Company
(Number), 2024
Figure 4-2: Global - PRMT5 Targeted Therapies Clinical Trials By Indication
(Number), 2024
Figure 4-3: Global - PRMT5 Targeted Therapies Clinical Trials By Location (Number) 2024
Figure 4-4: Global - PRMT5 Targeted Therapies Clinical Trials By Patient Segment
(Number), 2024
Figure 4-5: Global - PRMT5 Targeted Therapies Clinical Trials By Phase (Number) 2024

Figure 6-1: NCT05094336 Phase 1/2 Study – Initiation & Completion Year
Figure 6-2: NCT05528055 Phase 1 Study – Initiation & Completion Year
Figure 8 1: PRMT5 Targeted Therapies Market - Drivers & Opportunities
Figure 8 2: PRMT5 Targeted Therapies Market - Challenges & Restraints

List of Tables

Table 6-1: US – Ongoing Studies for PRMT5 Inhibitors
Table 6-2: UK – Ongoing Studies for PRMT5 Inhibitors
Table 6-3: EU – Ongoing Studies for PRMT5 Inhibitors
Table 6-4: China – Ongoing Studies for PRMT5 Inhibitors
Table 6-5: Canada – Ongoing Studies For PRMT5 Inhibitors